Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy…
The industry’s outlook remains uncertain as it navigates complex economic and political dynamics, reveals GlobalData
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Gilead Sciences
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis…
The approval could present a major challenge to Ocaliva (obeticholic acid), which was until recently the sole approved drug for…
Gilead Sciences announces $4 mn ALL4LIVER grant for viral hepatitis elimination by 2030
Indian organisations Chennai Liver Foundation and FIND receive the grant
US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment
The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk…
EMA validates Gilead’s Marketing Authorisation Application for Lenacapavir
Lenacapavir is an investigational, long-acting capsid inhibitor for the treatment of HIV-1 in people with limited therapy options
China Junshi’s potential COVID drug shows promise in small trial
The drug, called VV116, is a derivative of Gilead Sciences's COVID drug Remdesivir and was approved for use in moderate-to-severe…
Gilead withdraws use of Zydelig to treat cancer
The US FDA gave the drug an accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small…
Gilead submits Biologics Licence Application to USFDA for Bulevirtide
If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus…
Gilead Sciences launches Asia Pacific All4LIVER Grant 2021
The grant aims to empower organisations that can help bring liver health, in particular, viral hepatitis, to the forefront of…